Literature DB >> 8944363

Pathogenesis of Clostridium difficile-associated diarrhoea.

C Pothoulakis1.   

Abstract

Clostridium difficile is now regarded as a major enteric pathogen in hospitals and nursing-home facilities. The pathophysiology of this pathogen involves alterations of the indigenous colonic flora by antibiotics, ingestion of spores and colonization by C. difficile, followed by release of its toxins. Although most of the research on the intestinal effects of C. difficile had been focused on its enterotoxin or toxin A, recent results indicate that toxin B, the cytotoxin of C. difficile, is also active in human colon. The cloning and sequencing of the toxin A and toxin B gene and the identification of the GTP-binding protein Rho as their intracellular target represent major advances in our understanding of the mode of action of these toxins. An important characteristic of C. difficile infection is the dramatic inflammation seen in pseudomembranous colitis. Recent studies indicate that an interplay between lamina propria neuroimmune cells and intestinal epithelial cells may be central in pathogenesis of this toxin-mediated inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944363     DOI: 10.1097/00042737-199611000-00003

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  22 in total

Review 1.  Clostridial toxins: molecular probes of Rho-dependent signaling and apoptosis.

Authors:  D A Bobak
Journal:  Mol Cell Biochem       Date:  1999-03       Impact factor: 3.396

2.  Clostridium difficile-associated diarrhea - the new scourge of the health care facility.

Authors:  J Conly
Journal:  Can J Infect Dis       Date:  2000-01

3.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease.

Authors:  Séverine Péchiné; Claire Janoir; Anne Collignon
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 5.  Clostridium difficile-associated colitis.

Authors:  Mark W Hull; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-11       Impact factor: 3.275

Review 6.  Drug-induced diarrhoea.

Authors:  O Chassany; A Michaux; J F Bergmann
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

7.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

8.  Human Clostridium difficile infection: altered mucus production and composition.

Authors:  Melinda A Engevik; Mary Beth Yacyshyn; Kristen A Engevik; Jiang Wang; Benjamin Darien; Daniel J Hassett; Bruce R Yacyshyn; Roger T Worrell
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-31       Impact factor: 4.052

9.  Role of retinol in protecting epithelial cell damage induced by Clostridium difficile toxin A.

Authors:  Andressa A F L Maciel; Reinaldo B Oriá; Manuel B Braga-Neto; Andréa B Braga; Eunice B Carvalho; Herene B M Lucena; Gerly A C Brito; Richard L Guerrant; Aldo A M Lima
Journal:  Toxicon       Date:  2007-07-31       Impact factor: 3.033

10.  Performance of the TechLab C. DIFF CHEK-60 enzyme immunoassay (EIA) in combination with the C. difficile Tox A/B II EIA kit, the Triage C. difficile panel immunoassay, and a cytotoxin assay for diagnosis of Clostridium difficile-associated diarrhea.

Authors:  Heather Snell; Meredith Ramos; Sue Longo; Michael John; Zafar Hussain
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.